Why carry out this study?

The citrate-free ixekizumab formulation has been commercially available in the USA since August 2022 and has replaced the original formulation of ixekizumab.

However, patients’ experience with the new formulation has not been evaluated in a real-world setting.

Patient satisfaction with the first injection experience with citrate-free ixekizumab was evaluated in patients who had switched from the original ixekizumab formulation and in patients not previously exposed to ixekizumab.

What was learned from the study?

Significantly more patients were satisfied with citrate-free ixekizumab compared to original ixekizumab; and almost all patients who switched from original ixekizumab were definitely or mostly willing to continue using citrate-free ixekizumab.

Citrate-free ixekizumab was preferred and well accepted by most patients who switched from original ixekizumab.

Similar findings were seen across indications and regardless of prior biologic use.